To explore the possibility that intronic nucleotide substitutions at position c.375+5G represent an alternative mechanism for disruption of the TP53 gene, in this study we performed a comprehensive interrogation of these variants across a pan‐cancer cohort, complemented by mRNA and immunohistochemical analyses. The gene discussed is TP53; the disease is cancer.